Recursion Pharmaceuticals, Inc. (RXRX)
- Previous Close
4.7550 - Open
4.6550 - Bid 4.1200 x 7700
- Ask 4.1600 x 500
- Day's Range
4.1500 - 4.6750 - 52 Week Range
3.7900 - 12.3600 - Volume
31,365,866 - Avg. Volume
24,887,678 - Market Cap (intraday)
1.933B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5700 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.43
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
www.recursion.comRecent News: RXRX
View More
Performance Overview: RXRX
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXRX
View MoreValuation Measures
Market Cap
1.69B
Enterprise Value
1.28B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.94
Price/Book (mrq)
1.81
Enterprise Value/Revenue
21.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.51%
Return on Equity (ttm)
-86.10%
Revenue (ttm)
59.79M
Net Income Avi to Common (ttm)
-574.77M
Diluted EPS (ttm)
-1.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
500.45M
Total Debt/Equity (mrq)
9.95%
Levered Free Cash Flow (ttm)
-204.88M